COMPANY RESEARCHnGen combines AI and automated synthesis to optimize oral properties of nCycles and has a multi-target cardiometabolic collaboration with Novo. The company describes nCycles as fully synthetic macrocyclic NCEs.
Profile review: 2026-11-04 · Fields retain their individual source dates. Undisclosed values are not zero; early or historical events do not establish the latest financing. Awards and acquisitions are distinguished from equity rounds.
Disease tags match recorded text mentions and require program-level verification.
nGen combines AI and automated synthesis to optimize oral properties of nCycles and has a multi-target cardiometabolic collaboration with Novo. The company describes nCycles as fully synthetic macrocyclic NCEs.
2026-09-17: Orbis and Novo Nordisk sign oral macrocycle discovery partnership worth up to $1.4 billion
| Program / service | Target / indication | Representative stage | Evidence & scope |
|---|---|---|---|
| Undisclosed candidate | Not disclosed · Not disclosed | 未披露 | Quantitative human results not confirmed in this review |
Company-name matches are discovery leads; verify entity identity and transaction roles in the original source.
Orbis Medicines and Novo Nordisk signed a multi-target discovery and licensing agreement for orally bioavailable macrocycles in cardiometabolic disease. Orbis is eligible for up to $1.4 billion in upfront and future milestone payments, plus royalties, and Novo will make a strategic investment. Separate upfront and investment amounts were undisclosed; the headline value is not cash already paid.
Ahead of the AHA meeting, an original report reviewed enlicitide analyses across PREVENT cardiovascular risk groups and an open-label extension. LDL cholesterol reductions were broadly consistent across risk categories and persisted through Week 104. The extension selected participants who had tolerated and adhered to treatment and lacked a control group, limiting generalization of its long-term findings.
Aurinia reported LUPKYNIS net product sales of $232.4 million for the nine months ended September 30, 2026, up 18%, including $79.4 million in the third quarter, up 12%. Total company revenue also includes licensing, collaboration, and royalty income. These are commercialization results for an approved oral cyclic peptide, rather than a new indication approval or clinical endpoint readout.
A new review connects peptide structure, formulation, screening, and pharmacokinetic testing in an evidence-based framework for oral drug discovery. It distinguishes architecture-led libraries, oral optimization of existing hits, and hybrid approaches. The scope includes cyclic and noncyclic peptides; the proposed framework organizes development evidence rather than demonstrating a new therapy or clinical benefit.
Discussions are for signed-in members. Personal notes remain separate from company research.
Sign in to joinInclusion is not endorsement or partner qualification. Assess company claims, clinical evidence, and project-specific capabilities separately.
